do_not_disturb_altRecruitment Complete

Symptomatic Transthyretin Amyloid Cardiomyopathy

Bayer Identifier:
ALXN2060-TAC-302
ClinicalTrials.gov Identifier:
NCT04622046
EudraCT Number:
Not Available
EU CT Number:
Not Available
A Phase 3, Prospective, Multicenter, Open Label, 2-Part Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ALXN2060 in Japanese Participants With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Trial purpose

Key Participants Requirements

Sex

N/A

Age

N/A

    Trial summary

    Enrollment Goal
    N/A
    Trial Dates
    November 2020 - September 2025
    Phase
    Phase 3
    Could I Receive a placebo
    N/A
    Products
    Acoramidis (BAY3684938)
    Accepts Healthy Volunteer
    N/A

    Trial design

    A Phase 3, Prospective, Multicenter, Open Label, 2-Part Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ALXN2060 in Japanese Participants With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
    Trial Type
    Interventional
    Intervention Type
    N/A
    Trial Purpose
    N/A
    Allocation
    N/A
    Blinding
    N/A
    Assignment
    N/A
    Trial Arms
    N/A